AT1 — Atomo Diagnostics Share Price
0.000.00%
Last trade - 00:00- AU$19.18m
- AU$12.84m
- AU$2.54m
- 45
- 30
- 60
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.4 | ||
| Price to Tang. Book | 1.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53% | ||
| Return on Equity | -44.84% | ||
| Operating Margin | -235.75% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.54 | 5.37 | 6.72 | 12.34 | 2.54 | n/a | n/a | 54.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.
Directors
- John Kelly CEO
- Byron Darroch GMG
- Hans Fredman OTH
- Robert Snoch OTH
- Tharun Kuppanda SEC
- Gillian Nairn SEC
- Deborah Neff NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 1st, 2010
- Public Since
- April 16th, 2020
- No. of Shareholders
- 7,518
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 639,202,310
- Address
- Level 1, 3-5 George Street, Leichhardt, SYDNEY, 2040
- Web
- https://www.atomodiagnostics.com/
- Phone
- +61 290994750
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for AT1
Similar to AT1
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Atomo Diagnostics share price?
As of Today at 19:03 UTC, shares in Atomo Diagnostics are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Atomo Diagnostics share price performed this year?
Shares in Atomo Diagnostics last closed at AU$0.03 and the price had moved by -23.08% over the past 365 days. In terms of relative price strength the Atomo Diagnostics share price has underperformed the ASX All Ordinaries Index by -28.35% over the past year.
What are the analyst and broker recommendations for Atomo Diagnostics?
The overall consensus recommendation for Atomo Diagnostics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Atomo Diagnostics dividend yield?
Atomo Diagnostics does not currently pay a dividend.
Does Atomo Diagnostics pay a dividend?
Atomo Diagnostics does not currently pay a dividend.
When does Atomo Diagnostics next pay dividends?
Atomo Diagnostics does not currently pay a dividend.
How do I buy Atomo Diagnostics shares?
To buy shares in Atomo Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Atomo Diagnostics?
As of the previous close price of AU$0.03, shares in Atomo Diagnostics had a market capitalisation of AU$19.18m.
Where are Atomo Diagnostics shares listed?
Here are the trading details for Atomo Diagnostics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AT1
What kind of share is Atomo Diagnostics?
Based on an overall assessment of its quality, value and momentum Atomo Diagnostics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Atomo Diagnostics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Atomo Diagnostics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atomo Diagnostics. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +3.1%.
As of the last closing price of AU$0.03, shares in Atomo Diagnostics were trading +10.76% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Atomo Diagnostics PE Ratio?
The Atomo Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Atomo Diagnostics?
Atomo Diagnostics' management team is headed by:
- John Kelly - CEO
- Byron Darroch - GMG
- Hans Fredman - OTH
- Robert Snoch - OTH
- Tharun Kuppanda - SEC
- Gillian Nairn - SEC
- Deborah Neff - NID